TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03613974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: patients will receive different lidocaine concentrations
Study: NCT02850757

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: U shaped Guedl's airway
Description: To use U shaped Guedl's airway for assisting fiberoptic bronchoscope during endotracheal intubation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified William's airway
Description: Use Modified William's airway for assisting fiberoptic bronchoscope dduring endo tracheal intubation
Study: NCT01404104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus (pre surgery)
Description: Temsirolimus will be given to patients 12 weeks prior to surgery (with a one week off period right before the surgery date).
Study: NCT02189538

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ω-3 PUFA
Description: The patients are fed as long as the clinically required with the randomly attributed enteral solution.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low fat enteral diet
Description: The patients are fed as long as the clinically required with the randomly attributed enteral solution
Study: NCT01173666

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stenting angioplasty plus medical therapy
Description: Patients will be treated by stenting angioplasty of renal artery plus medical therapy. Medical therapy is based on antihypertensive, statin or antiplatelet drugs according to clinical indications.
Study: NCT03575494

Intervention type: OTHER
Intervention: Intraoral and Radiographic Dental Examination
Description: (ORTHOPANTOMOGRAPH® OP300 PANORAMIC, Instrumentarium Dental, Tuusula, Finland,63 kVp, 0.8 mA, 0.5 s).

Intervention type: OTHER
Intervention: Intraoral and Radiographic Dental Examination
Description: (ORTHOPANTOMOGRAPH® OP300 PANORAMIC, Instrumentarium Dental, Tuusula, Finland,63 kVp, 0.8 mA, 0.5 s).
Study: NCT03645213

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Box
Description: Virtual Reality box, a head-mounted display with stereo earphones transmits the cartoon image onto screens in front of the child's eyes. It was showed on Samsung Galaxy Note5 phone and Samsung Gear VR box /SM-R323N.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tablet Computer
Description: The tablet computer is a device that children watch on a 7-inch screen.
Study: NCT04362618

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Strengthening Training
Description: Muscle strengthening training will take place for a period of 12 weeks, in which participants will have 36 exercise sessions (18 at the hospital under supervision of a physiotherapist; 18 unsupervised at home) planned. Muscles of the leg (i.e. quadriceps, hip ab- and adductors) will be trained at 3 set of 10 repetitions at 80% of 1RM with the use of elastic bands. 1RM will be assessed at baseline and the exercise intensity will be progressively increased by 10% of 1RM every two sessions from 50 up to 70-80 % of 1RM. Every 6 sessions, the 1RM will be reassessed and the training resistances will be adapted.
Study: NCT01173666

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Medical therapy
Description: Patients will be treated by standard medical therapy. Medical therapy is based on antihypertensive, statin or antiplatelet drugs according with clinical indications.
Study: NCT04362618

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral graded activity
Description: Subjects will receive a behavioural treatment integrated within the concepts of operant conditioning with exercise therapy for a period of 12 weeks, in which the subjects will have maximum 36 BGA sessions (min. 13- max. 18 at the hospital under supervision of a physiotherapist; 18 unsupervised at home) planned. The purpose of BGA is to increase the level of activities in a time-contingent manner and increase the level of physical activity in the subject's daily lives. BGA consists of 3 phases: pain education (phase 1), treatment phase in which subjects increase their level of activity gradually (phase 2) and integration of learned principles in daily live (phase 3).
Study: NCT04063449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: endostar/PD-1 inhibitor
Description: Antiangiogenic therapy plus immunotherapy and chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: endostar
Description: Antiangiogenic therapy plus chemotherapy
Study: NCT04017598

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate
Description: 60 mg elemental iron as ferrous sulfate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous Bisglycinate
Description: 18 mg elemental iron as ferrous bisglycinate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of microcrystalline cellulose
Description: placebo
Study: NCT00460434

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TVT
Description: Prophylactic TVT

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham TVT
Study: NCT03451903

Intervention type: DRUG
Intervention: Actilyse
Description: Actilyse is the intra-venous agent used for intra-venous thrombolysis in the acute phase of cerebral infarction.
Study: NCT03054272

Intervention type: BEHAVIORAL
Intervention: Video
Description: A 13-minute video based on a suggested CICO algorithm from the Difficult Airway Society that was produced at the University of Montreal Simulation Centre using high-fidelity settings.

Intervention type: BEHAVIORAL
Intervention: Video
Description: A 13-minute video based on a suggested CICO algorithm from the Difficult Airway Society that was produced at the University of Montreal Simulation Centre using high-fidelity settings.
Study: NCT03451903

Intervention type: PROCEDURE
Intervention: Mechanical thrombectomy
Description: Mechanical thrombectomy is an endovascular procedure by which an arterial clot is retrieved, in order to reperfuse the brain.

Intervention type: PROCEDURE
Intervention: Mechanical thrombectomy
Description: Mechanical thrombectomy is an endovascular procedure by which an arterial clot is retrieved, in order to reperfuse the brain.
Study: NCT04364893

Intervention type: OTHER
Group type: OTHER
Intervention: Suspension or Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors
Description: Suspension or Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors

Intervention type: OTHER
Group type: OTHER
Intervention: Suspension or Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors
Description: Suspension or Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors
Study: NCT03106428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI7247
Description: The study will enroll patients with R/R AML/MM/DLBCL who will receive MEDI7247 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI7247
Description: The study will enroll patients with R/R AML/MM/DLBCL who will receive MEDI7247 IV
Study: NCT00390741

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Plus Program
Description: Those assigned to the treatment group were visited by an exercise trainer three times a week for the first two months of the study, two times per week during months three and four, one time per week during months five and six, two times a month during months seven and eight, and one time a month during months nine through twelve. During months seven through twelve of the study the trainer contacted the participant by telephone once each week during the weeks that he or she did not go the participants' home.
Study: NCT01493154

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA Vaccine
Description: Patients will receive intramuscular needle injections of pNGVL4a-CRT/E7 (detox) DNA vaccine using the TDS-IM device on Day 1, 22, and 43 for a total of three vaccinations per patient. One day prior to each DNA vaccination, the patient will receive a single low dose of 200 mg/m2 of cyclophosphamide intravenously. The DNA vaccine will be administered in a dose-escalating manner.
Study: NCT02517541

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SenSura Mio Convex Soft
Description: SenSura Mio Convex Soft is a CE marked ostomy product manufactured by Coloplast
Study: NCT01493154

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA Vaccine
Description: Patients will receive intramuscular needle injections of pNGVL4a-CRT/E7 (detox) DNA vaccine using the TDS-IM device on Day 1, 22, and 43 for a total of three vaccinations per patient. One day prior to each DNA vaccination, the patient will receive a single low dose of 200 mg/m2 of cyclophosphamide intravenously. The DNA vaccine will be administered in a dose-escalating manner.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA Vaccine
Description: Patients will receive intramuscular needle injections of pNGVL4a-CRT/E7 (detox) DNA vaccine using the TDS-IM device on Day 1, 22, and 43 for a total of three vaccinations per patient. One day prior to each DNA vaccination, the patient will receive a single low dose of 200 mg/m2 of cyclophosphamide intravenously. The DNA vaccine will be administered in a dose-escalating manner.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA Vaccine
Description: Patients will receive intramuscular needle injections of pNGVL4a-CRT/E7 (detox) DNA vaccine using the TDS-IM device on Day 1, 22, and 43 for a total of three vaccinations per patient. One day prior to each DNA vaccination, the patient will receive a single low dose of 200 mg/m2 of cyclophosphamide intravenously. The DNA vaccine will be administered in a dose-escalating manner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: A single low dose of 200 mg/m2 of cyclophosphamide (CTX) will be administered intravenously up to 24 hours (Day 0) prior to each DNA vaccination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: A single low dose of 200 mg/m2 of cyclophosphamide (CTX) will be administered intravenously up to 24 hours (Day 0) prior to each DNA vaccination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: A single low dose of 200 mg/m2 of cyclophosphamide (CTX) will be administered intravenously up to 24 hours (Day 0) prior to each DNA vaccination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: A single low dose of 200 mg/m2 of cyclophosphamide (CTX) will be administered intravenously up to 24 hours (Day 0) prior to each DNA vaccination.
Study: NCT03106428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI7247
Description: The study will enroll patients with R/R AML/MM/DLBCL who will receive MEDI7247 IV
Study: NCT01817296

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Testicular Biopsy
Description: Micro-dissection testicular sperm extraction for sperm retrieval
Study: NCT02486237

Intervention type: OTHER
Intervention: None, observational study
Description: None, it is an observational study
Study: NCT00003744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Study: NCT03573622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anpl-one SR Tab. 300mg
Description: Anpl-one SR Tab. 300mg tablets followed by Sarpodipil SR Tab. 300mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anpl-one SR Tab. 300mg
Description: Anpl-one SR Tab. 300mg tablets followed by Sarpodipil SR Tab. 300mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarpodipil SR Tab. 300mg
Description: Sarpodipil SR Tab. 300mg tablets followed by Anpl-one SR Tab. 300mg tablets
Study: NCT02450747

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A MULTIFOCAL
Description: Subjects will wear the test lens for four weeks.
Study: NCT02092909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMO-8400
Description: IMO-8400 at escalating dose levels by subcutaneous injection
Study: NCT00005713

Intervention type: BEHAVIORAL
Intervention: Continuing, preventative care
Description: Training for intervention clinic staff was based on National Asthma Education and Prevention Program guidelines for the diagnosis and management of asthma, and included screening to identify new cases and health education to improve family management.
Study: NCT01535261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg/0.05 ml
Description: Patients will receive the first dose at Baseline, as an intravitreal injection with a standard dose of 0.5 mg/0.05 ml. Patients will receive at least 3 study treatments at monthly intervals (Day 1, Month 1 and Month 2). The last mandatory dose during treatment initiation will be administered approximately 60 days after the first study treatment. If there is no improvement in VA over the course of the first 3 injections, continued treatment is not recommended and the patient may receive alternative treatment at the investigator's discretion.
Study: NCT03573622

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sarpodipil SR Tab. 300mg
Description: Sarpodipil SR Tab. 300mg tablets followed by Anpl-one SR Tab. 300mg tablets
Study: NCT01857245

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Models (mDOT and CGT) of HCV Care
Description: Modified Directly Observed therapy (mDOT) and concurrent group treatment (CGT) are on-site HCV treatment models.
Study: NCT01426672

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monovision Correction (with the help of glasses or contact lenses)
Study: NCT02502942

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Upper Airway Muscle Exercise
Description: Patients will use an individualized oral retainer device for upper airway muscle training exercises daily for 20 minutes each day (10 minutes in the morning and 10 minutes in the afternoon/evening) for 6 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Upper Airway Muscle Exercise
Description: Patients will use an individualized oral retainer device for upper airway muscle training exercises daily for 20 minutes each day (10 minutes in the morning and 10 minutes in the afternoon/evening) for 6 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Upper Airway Muscle Exercise
Description: Patients will use an individualized oral retainer device for upper airway muscle training exercises daily for 20 minutes each day (10 minutes in the morning and 10 minutes in the afternoon/evening) for 6 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sham Exercise
Description: Patients will be given an individualized oral retainer device and instructed to do deep breathing exercise twice daily for 6 weeks.
Study: NCT00811499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-371797, p38 inhibitor; oral
Description: multiple dose, single schedule
Study: NCT03310814

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized nutrition
Description: Receives individualized nutrition information

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Personalized nutrition
Description: Receives individualized nutrition information
Study: NCT04371380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir extended release suspension for injection (long-acting)
Description: Cabotegravir long-acting will be a sterile white to slightly pink suspension containing 200 mg per mL of GSK1265744 as free acid for administration by intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine extended release suspension for injection (long-acting)
Description: Rilpivirine long-acting will be a sterile white suspension containing 300 mg per mL of rilpivirine as the free base for administration by intramuscular injection.
Study: NCT00811499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-371797, p38 inhibitor; oral
Description: multiple dose, single schedule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo; oral
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo; oral
Description: multiple dose, single schedule
Study: NCT02997852

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy dog visitation
Description: The TDV will consist of a 10-minute visit from the same Faithful Paws animal handler and her dog. Each therapy dog meets obedience, temperament, and health standards appropriate to therapy dog visitation in hospital settings. The dog will be leashed and under control of the animal handler and the TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. Visual and tactile contact with the dog will be promoted by the animal handler. Per hospital protocol, the patient will be assisted in washing his/her hands before and after the TDV and the dog will be placed on the bed or remain at the bedside in close proximity allowing petting. A clean sheet will be placed over the patient when the dog is placed on the bed. The research staff will collect data before and after each arm of the study.
Study: NCT01248858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2126458 and GSK1120212
Description: GSK2126458 and GSK1120212 are experimental treatments for patients with cancer.
Study: NCT01640366

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO
Description: Single-use Negative Pressure Wound Therapy System
Study: NCT01716728

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: enzyme analysis
Study: NCT04154228

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/MR scan
Description: Patients will undergo 18F-FDG PET/CT scans before therapy initiation, interim after 2/3 treatment cycles and end of treatment after therapy completion, as part of their routine evaluation, as well as additional follow-up scans, as clinically indicated and requested by referring physicians. Given signed written informed-consent forms, patients will undergo at each time point, immediately after completion of PET/CT, a PET/MR scan, following the same single injection of 18F-FDG. Standard preparation and acquisition protocols for FDG PET imaging will be employed.~PET/MR imaging will include conventional sequences as T1, T2, diffusion weighted imaging, and advanced vascular imaging (DCE-MRI).
Study: NCT03216850

Intervention type: DEVICE
Intervention: Sublingual microcirculation assessment
Description: Non-invasive investigation of the endothelial glycocalyx in the sublingual microcirculation.
Study: NCT03377777

Intervention type: OTHER
Intervention: No intervention
Study: NCT00838565

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous infusion on three consecutive months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dose level 1
Description: intravenous infusion on three consecutive months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dose level 2
Description: intravenous infusion on three consecutive months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dose level 3
Description: intravenous infusion on three consecutive months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dose level 4
Description: intravenous infusion on 3 consecutive months
Study: NCT03080103

Intervention type: PROCEDURE
Intervention: Laparoscopic or Open appendectomy
Description: Laparoscopic three-port or single-port appendectomy; or conventional McBurney laparotomic appendectomy; or open appendectomy performed through midline incision

Intervention type: DRUG
Intervention: Antibiotic-first therapy
Description: Patients treated with antibiotics as first-line approach
Study: NCT01485458

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early surgery
Description: Surgery within 24 hours after admission

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed surgery
Description: Surgery more than 2 weeks after injury
Study: NCT01857245

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Models (mDOT and CGT) of HCV Care
Description: Modified Directly Observed therapy (mDOT) and concurrent group treatment (CGT) are on-site HCV treatment models.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Models (mDOT and CGT) of HCV Care
Description: Modified Directly Observed therapy (mDOT) and concurrent group treatment (CGT) are on-site HCV treatment models.
Study: NCT04596917

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preferred music listening
Description: The preferred music listening group will receive 15 minute patient-preferred music listening selection intervention in the Prep Room and unlimited music listening selection intervention in the PACU once cognitively ready until discharge criteria met.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation breathing narrative over hypnotic music listening
Description: The relaxation breathing group will receive the relaxation and breathing instructions over soft monotone hypnotic music in the PreOp unit before surgery and then in the PACU once cognitively ready to listen to the hypnotic music until discharge criteria met.
Study: NCT01289834

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hi-Fatigue Bone Cement
Description: Hi-Fatigue bone cement is a new development of Aap Biomaterials, GmbH \& Co that has not yet been tested in the clinical setting. Hi-Fatigue has a medium to low viscosity. Laboratory tests confirm Hi-Fatigue bone cement to have properties equivalent to or better than the golden standard bone cement Palacos. Hi-Fatigue is to be used without pre-chilling. When mixed at a room temperature of 21°C Hi-Fatigue has a low initial viscosity improving mixing and theoretically reducing the porosity of the cured cement.
Study: NCT01465958

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GAMUNEX-C
Description: GAMUNEX-C Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified, Intravenous Administration: 200-600 mg/kg per intravenous infusion every 3-4 weeks
Study: NCT01289834

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Palacos Bone Cement
Description: Palacos Bone Cement has been used for 48 years and has a good reputation as the gold standard among bone cements (3). It is a high-viscosity cement with rapid application that makes it advantageous for use in orthopedic joint surgery. Palacos cement was developed in order to allow hand mixing of monomers and polymers in a dish in the operating room. Air pollution with toxic monomers in the operating room was a problem that was primarily solved by exhaust ventilation, later supplemented with vacuum mixing
Study: NCT04322448

Intervention type: DEVICE
Intervention: Mechanomyography (MMG)
Description: MMG, as described in the cohort descriptions, to be used during surgery to see if they are predictive of patient outcomes.

Intervention type: DEVICE
Intervention: Mechanomyography (MMG)
Description: MMG, as described in the cohort descriptions, to be used during surgery to see if they are predictive of patient outcomes.